Anakinra is a recombinant human IL-1 receptor antagonist (IL-1ra) authorized for use in treating rheumatoid arthritis and other illnesses characterized by inflammation and has been found to reduce inflammatory markers such as CRP, ferritin, D-dimers, and IL-6 [17]. Here, IL6 is linked to rheumatoid arthritis.